Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Ningna Weng

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5109900701. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 5 papers

Papers 13

  1. Scoparone induces mitophagy and apoptosis via ROS accumulation in pancreatic cancer cells. Co-author DOI 10.1016/j.crtox.2026.100281↗
  2. Pan-cancer analysis identifies GPRIN1 as a prognostic biomarker and promoter of cell proliferation in pancreatic cancer. Co-author DOI 10.1016/j.yexmp.2026.105061↗
  3. Correction: Osthole induces accumulation of impaired autophagosome against pancreatic cancer cells. Co-author DOI 10.1038/s41598-026-42597-7↗
  4. Chrysosplenetin-induced TMED3 aggregation triggers unfolded protein response in pancreatic cancer. First author DOI 10.1038/s44321-026-00506-5↗
  5. Agrimol B inhibits pancreatic ductal adenocarcinoma by induction of lethal mitophagy through decreasing mitochondrial transcription termination factor 3. Co-author DOI 10.1093/pcmedi/pbag009↗
  6. Author Correction: Osthole induces accumulation of impaired autophagosome against pancreatic cancer cells. Co-author DOI 10.1038/s41598-025-97328-1↗
  7. Osthole induces accumulation of impaired autophagosome against pancreatic cancer cells. Co-author DOI 10.1038/s41598-024-81911-z↗
  8. Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.apsb.2022.01.018↗
  9. Serum Nardilysin as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm11113101↗
  10. Repurposing antitussive benproperine phosphate against pancreatic cancer depends on autophagy arrest. Co-author DOI 10.1002/1878-0261.12854↗
  11. Identification of Novel Molecular Therapeutic Targets and Their Potential Prognostic Biomarkers Among Kinesin Superfamily of Proteins in Pancreatic Ductal Aden… Co-author DOI 10.3389/fonc.2021.708900↗
  12. ABO blood type, smoking status, other risk factors and prognosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/md.0000000000019413↗
  13. Evaluation of the target genes of arsenic trioxide in pancreatic cancer by bioinformatics analysis. Co-author DOI 10.3892/ol.2019.10889↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qing Zhu · 8 shared papers, 2019–2026 · strength 1.57
  2. Jinlu Liu · 3 shared papers, 2022–2026 · strength 0.82
  3. Qing Zhu · 2 shared papers, 2025–2026 · strength 0.58
  4. Zhe Zhang · 3 shared papers, 2021–2026 · strength 0.50
  5. Sha Huang · 2 shared papers, 2024–2025 · strength 0.50
  6. XunJie Cao · 1 shared paper, 2026 · strength 0.43
  7. Sha Huang · 1 shared paper, 2026 · strength 0.36
  8. S. Huang · 1 shared paper, 2026 · strength 0.32
  9. Ying Zheng · 1 shared paper, 2026 · strength 0.32
  10. Yifei Ma · 1 shared paper, 2026 · strength 0.32
  11. Qunli Xiong · 2 shared papers, 2021–2022 · strength 0.27
  12. Yongfeng Xu · 2 shared papers, 2021–2022 · strength 0.27
  13. Qi Zhang · 1 shared paper, 2026 · strength 0.26
  14. Tingbo Liang · 1 shared paper, 2026 · strength 0.26
  15. Yi Zang · 1 shared paper, 2026 · strength 0.26
  16. Suxia Han · 2 shared papers, 2019–2022 · strength 0.21
  17. Congya Zhou · 2 shared papers, 2019–2020 · strength 0.20
  18. Zhiwei Zhang · 1 shared paper, 2022 · strength 0.15
  19. Xing Huang · 1 shared paper, 2022 · strength 0.13
  20. Canhua Huang · 1 shared paper, 2022 · strength 0.13
  21. Ajay Goel · 1 shared paper, 2022 · strength 0.13
  22. Yang Yang · 1 shared paper, 2021 · strength 0.12
  23. Huanyu Zhang · 1 shared paper, 2021 · strength 0.12
  24. Qifu Li · 1 shared paper, 2021 · strength 0.12
  25. Shaojiang Zheng · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.